Purpose: Gain-of-function mutations in the KCNT1 gene have been reported in a number of drug resistant epilepsy syndromes including Epilepsy of Infancy with Migrating Focal Seizures. Quinidine, a potassium channel blocker, has been proposed as a potential therapeutic agent with only a few patients reported in the literature to have received it. Here we report 3 additional children, with such KCNT1 mutations and refractory seizures, who received quinidine therapy. Methods: Retrospective chart review of 3 children with KCNT1 mutations, of ages 3 months, 9 years and 13 years old. Video-EEG documented seizure type and frequency. Seizure frequency was compared before and after quinidine initiation. We then analyzed seizure response (defined as >50% reduction in seizure frequency) as it related to age in our 3 reported children, an additional 2 previously seen by us in our center, and an additional 3 reported in the literature (total 8 cases). Results: In our report, the 3-month-old infant responded to quinidine, while the two older children did not. Using a cutoff of 4 years of age, review of the total of 8 cases, five from our center, revealed that all patients younger than 4 years responded to quinidine (4/4), while none of the ones older than 4 years did (0/4). Conclusion: The above-mentioned findings support performance of prospective controlled studies of quinidine efficacy in children with KCNT1 gain-of-function mutations that control for age as a possible variable affecting response.
Introduction
The KCNT1 gene codes for a voltage-dependent sodiumactivated potassium channel. Gain-of-function mutations of this gene have been associated with several drug resistant epilepsy syndromes. Quinidine ameliorates the resultant abnormally increased potassium currents in-vitro and its clinical use has recently been reported in a total of 5 cases, 2 of them from our institution. Response was observed in some, but not in others [1] [2] [3] [4] . Here we report 3 additional patients and review the prior cases to raise the possibility that younger patients with KCNT1 mutations may be more likely to respond to quinidine.
Case reports

Patient 1
A 13-year-old male who developed focal seizures few days after birth and continued to have multiple daily seizures throughout his infancy and childhood. These were refractory to six antiepileptic drugs, vagal nerve stimulation and ketogenic diet. He never developed speech or independent ambulation, and had diffuse hypertonia. Initial extensive metabolic and genetic workup was negative. At the age of 9 years, whole exome sequencing showed a KCNT1 de novo mutation c.1421G > A (disease-causing by ACMG criteria, previously reported). During the month prior to admission, he was having an average of 0.82 seizures/day (mother meticulously kept a daily seizure diary). Video-EEG during hospitalization showed asymmetric tonic seizures with concurrent bilateral electrodecremental fast activity. Before starting quinidine, he had one seizure in 36 h of monitoring. He was started on quinidine, 4 mg/kg TID, which was gradually increased while monitoring his QTc interval over three days to 36 mg/kg/day, divided TID. He did not have any additional seizures and was discharged. However, at home, he continued to have an average of 0.47 seizures/day over the next five months. He was readmitted with video-EEG showing 7 seizures in 5 days (1.4/day). The dose of quinidine was increased to 45 mg/kg/day but it resulted in prolongation of the QTc to 568 ms, so the dose was reduced, and quinidine was considered not to have been effective.
Patient 2
A 3-month-old male who started having focal seizures at 3 days of age. These were refractory to eight antiepileptics and to ketogenic diet. His development was initially appropriate, except for mild hypertonia. Metabolic workup was negative. Epilepsy gene panel revealed a KCNT1 de novo mutation (c.2965G > T), previously not reported in gene or public SNP databases, and predicted to be likely pathogenic. When seen for initiation of quinidine therapy, he was having multiple clinical seizures per day consisting of eye deviation to one side or the other, usually with tonic stiffening more on the side of the eye deviation. In about 1/3 of these seizures he would become cyanotic as well. He was admitted and monitoring showed 1-30 s focal onset seizures, bilaterally independent, usually consisting of sharp evolving theta (less frequently beta) electrographic seizure activity that often spread contralaterally. He was started on quinidine, 10 mg/kg/day divided TID, which was gradually increased over 6 days to 40 mg/kg/day, divided TID. Seizure frequency by video-EEG showed a baseline of 89 seizures/28.5 h of monitoring (3.2 seizures/h), 105 seizures during 99.5 h of monitoring (1.1 seizures/h) during titration, and 39 seizures in 38.1 h of monitoring (1.0 seizure/h) on the final dose of 40 mg/kg/day. Furthermore, the seizures were much less severe, with complete cessation of the cyanotic spells. He was considered to have responded to quinidine and discharged on the same dose.
Patient 3
A 9-year-old male who started having focal seizures at 4 years of age. These were refractory to three antiepileptics. He reached developmental milestones at the appropriate ages, and is currently developmentally normal, except for known ADHD. Metabolic workup was negative. Epilepsy gene panel revealed a KNCT1 de novo mutation (c.1193G > A), previously reported to be diseasecausing. When seen for initiation of quinidine therapy, he was having 2-4 tonic seizures per night, lasting 5-15 s, consisting of sudden arousal and total body stiffening. In addition, he was having 4 GTC per month, lasting 10-15 min, usually during wakefulness. He was admitted and started on quinidine, 11 mg/kg/day divided TID, planned to be increased to a goal of 24 mg/kg/day. EEG monitoring showed 2 episodes on the first night whereby delta sleep is interrupted for 1-2 s with low amplitude and fast activity, before returning to baseline within 3-4 s, that correlated clinically with the patient's typical seizure. He had 5 additional episodes in the remaining 2 days of monitoring. He was discharged on 18 mg/ kg/day (serum quinidine level of 0.9 mg/ml), because the dose of 24 mg/kg/day led to prolongation of his QT interval (460 msec). Two weeks later, he was readmitted for worsening of seizures, with 13 events captured on video-EEG on the first night. During this admission, quinidine was gradually titrated from 18 mg/kg/day, to a goal of 60 mg/kg/day. However, video-EEG continued to show an average of 2-4 electroclinical seizures an hour, every night for 4 consecutive nights, despite achieving a therapeutic quinidine serum level of 3.2 mg/ml. Quinidine was discontinued on discharge, as it did not seem to improve clinical or electrographic seizure activity.
Discussion
We report here three patients in whom the effect of quinidine was studied by video-EEG monitoring. Considering response to quinidine as >50% reduction in seizure frequency, the younger Table 1 Quinidine response in KCNT1 cases reported in the literature and above-described patients. a Serum quinidine level was 2.6 mg/ml on the dose of 45 mg/kg/day and 1.1 on 37.5 mg/kg/day.
b Baseline QTc was 448 msec and daily monitoring showed that it fluctuated increasing to a maximum of 478 and settling at 469 on discharge, with a quinidine level of 0.4 mg/ml at that time. c Serum quinidine level was 0.4 mg/ml on the dose of 18 mg/kg/day (on admission) and 3.2 on 60 mg/kg/day (on discharge).
patient responded, while the older two did not. These findings are similar to our prior report in which the younger, but not the older, patient responded (Table 1) . This raises the possibility that response may be age-dependent. Given the prior reports (Table 1) , we calculated that 4/4 patients <4 years of age responded, and 0/4 patients >4 years did not (p = .029, Fisher exact test). This suggests that younger age may be associated with a better likelihood to respond. However, we consider this analysis as merely exploratory. If confirmed in future long term prospective studies such an effect may be due to one or more factors such as potentially better permeability of quinidine across the blood brain barrier in younger individuals, or due to the effects of long term epilepsy in predisposing to even more severe drug resistance in older patients. We would like to caution, again, that our analysis is susceptible to reporting bias. Physicians may be more likely to report positive responses to quinidine than negative ones. Our observations nevertheless emphasize the importance of studying more patients and performing controlled trials taking into consideration age as a potential confounding variable.
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